{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:20:41Z","timestamp":1771305641081,"version":"3.50.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010426","name":"UGC-DAE\u00a0Consortium for Scientific Research, University Grants Commission","doi-asserted-by":"publisher","award":["No. F.15-1\/2017\/PDFWM-2017-18-MAD-46619(SA-II)"],"award-info":[{"award-number":["No. F.15-1\/2017\/PDFWM-2017-18-MAD-46619(SA-II)"]}],"id":[{"id":"10.13039\/501100010426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-023-00993-5","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T05:07:00Z","timestamp":1698901620000},"page":"297-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target"],"prefix":"10.1007","volume":"37","author":[{"given":"Sheetal","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khushboo","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Pushker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachna","family":"Meel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehar Chand","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"993_CR1","first-page":"115","volume":"5","author":"DE Bejar","year":"2014","unstructured":"Bejar DE, Huh WW. Rhabdomyosarcoma in adolescent and young adult patients:currentperspectives. Health Med Ther. 2014;5:115\u201325.","journal-title":"Health Med Ther"},{"issue":"1","key":"993_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0039-6257(02)00415-0","volume":"48","author":"JA Shields","year":"2003","unstructured":"Shields JA, Shields CL. Rhabdomyosarcoma: review for the ophthalmologist. Surv Ophthalmol. 2003;48(1):39\u201357.","journal-title":"Surv Ophthalmol"},{"key":"993_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clon.2012.07.009","volume":"25","author":"SA Terezakis","year":"2013","unstructured":"Terezakis SA, Wharam MD. Radiotherapy for rhabdomyosarcoma:indications and outcome. Clin Oncol R CollRadiol. 2013;25:27\u201335.","journal-title":"Clin Oncol R CollRadiol"},{"key":"993_CR4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-009-0775-1","volume":"454","author":"S Viswanathan","year":"2009","unstructured":"Viswanathan S, George S, Ramadwar M, et al. Extraconal orbital tumors in children\u2014a spectrum. Virchows Arch. 2009;454:703\u201313.","journal-title":"Virchows Arch"},{"key":"993_CR5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1126\/science.8383879","volume":"259","author":"SJ Tapscott","year":"1993","unstructured":"Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 1993;259:1450\u20133.","journal-title":"Science"},{"key":"993_CR6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0009-9260(98)80009-3","volume":"53","author":"SA Sohaib","year":"1998","unstructured":"Sohaib SA, Moseley I, Wright JE. Orbital rhabdomyosarcoma-the radiological characteristics. Clin Radiol. 1998;53:357\u201362.","journal-title":"Clin Radiol"},{"key":"993_CR7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L","volume":"61","author":"HM Maurer","year":"1988","unstructured":"Maurer HM, Beltangady M, Gehan EA, et al. The intergroup rhabdomyosarcoma study-IA final report. Cancer. 1988;61:209\u201320.","journal-title":"Cancer"},{"key":"993_CR8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298:1912\u201334.","journal-title":"Science"},{"key":"993_CR9","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","volume":"19","author":"DR Robinson","year":"2000","unstructured":"Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548\u201357.","journal-title":"Oncogene"},{"key":"993_CR10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Du Zhenfang","year":"2018","unstructured":"Zhenfang Du, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:58.","journal-title":"Mol Cancer"},{"issue":"13","key":"993_CR11","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2174\/138955708786369591","volume":"8","author":"M Krug","year":"2008","unstructured":"Krug M, Hilgeroth A. Recent advances in the development of multi- kinase inhibitors. Mini Rev Med Chem. 2008;8(13):1312\u201327.","journal-title":"Mini Rev Med Chem"},{"issue":"2","key":"993_CR12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","volume":"2","author":"F Broekman","year":"2011","unstructured":"Broekman F, Giovannetti E, Peters G. Tyrosine kinase inhibitors: multi- targeted or single-targeted? World J Clin Oncol. 2011;2(2):80\u201393.","journal-title":"World J Clin Oncol"},{"issue":"5","key":"993_CR13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","volume":"38","author":"JH Cho","year":"2020","unstructured":"Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non- small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488\u201395.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"993_CR14","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/JCO.2019.37.15_suppl.9007","volume":"37","author":"PA Janne","year":"2019","unstructured":"Janne PA, Neal JW, Camidge DR, et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. J Clin Oncol. 2019;37(15_suppl):9007.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"993_CR15","doi-asserted-by":"crossref","first-page":"9514","DOI":"10.1200\/JCO.2020.38.15_suppl.9514","volume":"38","author":"X Le","year":"2020","unstructured":"Le X, Goldman JW, Clarke JM, et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. J Clin Oncol. 2020;38(15_suppl):9514.","journal-title":"J Clin Oncol"},{"key":"993_CR16","first-page":"423","volume":"6","author":"P Chia","year":"2014","unstructured":"Chia P, Mitchell P, Dobrovic A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. ClinEpidemiol. 2014;6:423\u201332.","journal-title":"ClinEpidemiol"},{"issue":"21","key":"993_CR17","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"A Shaw","year":"2014","unstructured":"Shaw A, Ou S, Bang Y, et al. Crizotinib in ROS1-rearranged non-small- cell lung cancer. N Engl J Med. 2014;371(21):1963\u201371.","journal-title":"N Engl J Med"},{"issue":"4","key":"993_CR18","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30207-9","volume":"20","author":"R Stirrups","year":"2019","unstructured":"Stirrups R. Neratinib and capecitabine for breast cancer brain metasta- ses. Lancet Oncol. 2019;20(4): e197.","journal-title":"Lancet Oncol"},{"issue":"7","key":"993_CR19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2217\/fon-2019-0719","volume":"16","author":"A Nasrazadani","year":"2020","unstructured":"Nasrazadani A, Brufsky A. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. Future Oncol. 2020;16(7):247\u201354.","journal-title":"Future Oncol"},{"issue":"10064","key":"993_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocel- lular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366.","journal-title":"Lancet"},{"issue":"1","key":"993_CR21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"G Abou-Alfa","year":"2018","unstructured":"Abou-Alfa G, Meyer T, Cheng A, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54\u201363.","journal-title":"N Engl J Med"},{"issue":"15","key":"993_CR22","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2020.38.15_suppl.4507","volume":"38","author":"Q Li","year":"2020","unstructured":"Li Q, Qin S, Gu S, et al. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: a randomized, placebo-controlled, double-blind, phase III study. J Clin Oncol. 2020;38(15):4507.","journal-title":"J Clin Oncol"},{"issue":"7","key":"993_CR23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"T Choueiri","year":"2016","unstructured":"Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a ran- domised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327.","journal-title":"Lancet Oncol"},{"issue":"11","key":"993_CR24","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569\u201375.","journal-title":"JAMA Oncol"},{"issue":"5","key":"993_CR25","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1634\/theoncologist.2019-0391","volume":"25","author":"Y Liu","year":"2020","unstructured":"Liu Y, Hu X, Jiang J, et al. A prospective study of apatinib in patients with extensive-stage small cell lung cancer after failure of two or more lines of chemotherapy. Oncologist. 2020;25(5):e833\u201342.","journal-title":"Oncologist"},{"key":"993_CR26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-018-0113-x","volume":"7","author":"E Poddubskaya","year":"2018","unstructured":"Poddubskaya E, Baranova M, Allina D, et al. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocar- cinoma. Exp Hematol Oncol. 2018;7:21.","journal-title":"Exp Hematol Oncol"},{"issue":"15_suppl","key":"993_CR27","doi-asserted-by":"crossref","first-page":"9515","DOI":"10.1200\/JCO.2020.38.15_suppl.9515","volume":"38","author":"JFCG Gainor","year":"2020","unstructured":"Gainor JFCG, Kim D-W, et al. Registrational dataset from the phase I\/ II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38(15_suppl):9515.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"993_CR28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1200\/JCO.2020.38.15_suppl.109","volume":"38","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Hu MIN, Gainor JF, et al. Clinical activity of the RET inhibi- tor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J Clin Oncol. 2020;38(15_suppl):109.","journal-title":"J Clin Oncol"},{"issue":"1","key":"993_CR29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","volume":"26","author":"A Drilon","year":"2020","unstructured":"Drilon A, Clark J, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47\u201351.","journal-title":"Nat Med"},{"issue":"7","key":"993_CR30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","volume":"8","author":"SK Pal","year":"2018","unstructured":"Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previ- ously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 2018;8(7):812.","journal-title":"Cancer Discov"},{"key":"993_CR31","first-page":"2443","volume":"10","author":"M AbbaspourBabaei","year":"2016","unstructured":"AbbaspourBabaei M, Kamalidehghan B, Saleem M, et al. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des DevelTher. 2016;10:2443\u201359.","journal-title":"Drug Des DevelTher"},{"issue":"26","key":"993_CR32","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","volume":"31","author":"FS Hodi","year":"2013","unstructured":"Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melano- mas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J ClinOncol. 2013;31(26):3182\u201390.","journal-title":"J ClinOncol"},{"key":"993_CR33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fonc.2018.00135","volume":"8","author":"L Mei","year":"2018","unstructured":"Mei L, Du W, Idowu M, et al. Advances and challenges on management of gastrointestinal stromal tumors. Front Oncol. 2018;8:135.","journal-title":"Front Oncol"},{"issue":"6","key":"993_CR34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1165::AID-CNCR21>3.0.CO;2-5","volume":"80","author":"WJ Lawrence","year":"1997","unstructured":"Lawrence WJ, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma study group. Cancer. 1997;80(6):1165\u201370.","journal-title":"Cancer"},{"key":"993_CR35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1479-5876-9-64","volume":"9","author":"J Hou","year":"2011","unstructured":"Hou J, Dong J, Sun L, et al. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J Transl Med. 2011;9:64.","journal-title":"J Transl Med"},{"issue":"58","key":"993_CR36","first-page":"105e110","volume":"2019","author":"L Lim","year":"2019","unstructured":"Lim L, Wu CC, Hsu YT, et al. Clinical significance of c-Met and phospho-c-Met (Tyr1234\/1235) in ovarian cancer. Taiwan J Obstet Gynecol. 2019;2019(58):105e110.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"993_CR37","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1073\/pnas.0508776103","volume":"103","author":"GA Smolen","year":"2006","unstructured":"Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA- 665752. Proc Natl Acad Sci USA. 2006;103:2316\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"993_CR38","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-06-3495","volume":"67","author":"B Lutterbach","year":"2007","unstructured":"Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007;67:2081\u20138.","journal-title":"Cancer Res"},{"issue":"5","key":"993_CR39","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1083\/jcb.137.5.1057","volume":"137","author":"S Anastasi","year":"1997","unstructured":"Anastasi S, Giordano S, Sthandier O, et al. A natural hepatocyte growth factor\/scatter factor autocrine loop in myoblast cells and the effect of the constitutive met kinase activation on myogenic differentiation. J Cell Biol. 1997;137(5):1057\u201368.","journal-title":"J Cell Biol"},{"issue":"13","key":"993_CR40","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-07-4446","volume":"14","author":"FD Camassei","year":"2008","unstructured":"Camassei FD, McDowell HP, Deloris MA, et al. Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res. 2008;14(13):4119\u201327.","journal-title":"Clin Cancer Res"},{"key":"993_CR41","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ijc.28246","volume":"134","author":"JD Paccez","year":"2014","unstructured":"Paccez JD, Vogelsang M, Parker MI, et al. The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. Int J Cancer. 2014;134:1024\u201333.","journal-title":"Int J Cancer"},{"key":"993_CR42","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1158\/0008-5472.CAN-10-0391","volume":"70","author":"F Huang","year":"2010","unstructured":"Huang F, Hurlburt W, Greer A, et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS- 754807, in a human rhabdomyosarcoma model. Cancer Res. 2010;70:7221\u201331.","journal-title":"Cancer Res"},{"key":"993_CR43","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","volume":"37","author":"RI Nicholson","year":"2001","unstructured":"Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9\u201315.","journal-title":"Eur J Cancer"},{"key":"993_CR44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdh011","volume":"15","author":"G Selvaggi","year":"2004","unstructured":"Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15:28\u201332.","journal-title":"Ann Oncol"},{"issue":"7","key":"993_CR45","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1365-2559.2009.03303.x","volume":"54","author":"B Grass","year":"2009","unstructured":"Grass B, Wachtel M, Behnke S, et al. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2\u03b2 as biomarkers for rhabdomyosarcoma diagnostics. Histopathology. 2009;54(7):873\u20139.","journal-title":"Histopathology"},{"issue":"9","key":"993_CR46","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.3800636","volume":"19","author":"R Ganti","year":"2006","unstructured":"Ganti R, Skapek SX, Zhang J, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonalrhabdomyosarcoma. Mod Pathol. 2006;19(9):1213\u201320.","journal-title":"Mod Pathol"},{"issue":"5","key":"993_CR47","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2005.03.4934","volume":"24","author":"M Wachtel","year":"2006","unstructured":"Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol. 2006;24(5):816\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"993_CR48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/1097-0215(20000701)87:1<29::AID-IJC5>3.0.CO;2-J","volume":"87","author":"C Ricci","year":"2000","unstructured":"Ricci C, Landuzzi L, Rossi I, et al. Expression of HER\/erbB family of receptor tyrosine kinases and induction of differen- tiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int J Cancer. 2000;87(1):29\u201336.","journal-title":"Int J Cancer"},{"issue":"17","key":"993_CR49","first-page":"3898","volume":"56","author":"CD Giovanni","year":"1996","unstructured":"Giovanni CD, Landuzzi L, Frabetti F, et al. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Can Res. 1996;56(17):3898\u2013901.","journal-title":"Can Res"},{"issue":"1","key":"993_CR50","doi-asserted-by":"crossref","first-page":"e5772","DOI":"10.1097\/MD.0000000000005772","volume":"96","author":"YZ Danz","year":"2017","unstructured":"Danz YZ, Zhang Y, Li JP, et al. High VEGFR1\/2 expression levels are predictors of poor survival in patients with cervical cancer. Medicine. 2017;96(1):e5772.","journal-title":"Medicine"},{"key":"993_CR51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2004.00.3467","volume":"24","author":"S Juttner","year":"2006","unstructured":"Juttner S, Wissmann C, Jons T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J ClinOncol. 2006;24:228\u201340.","journal-title":"J ClinOncol"},{"key":"993_CR52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/cncr.11073","volume":"97","author":"M Arinaga","year":"2003","unstructured":"Arinaga M, Noguchi T, Takeno S, et al. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003;97:457\u201364.","journal-title":"Cancer"},{"key":"993_CR53","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/path.1467","volume":"201","author":"PO Van Trappen","year":"2003","unstructured":"Van Trappen PO, Steele D, Lowe DG, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol. 2003;201:544\u201354.","journal-title":"J Pathol"},{"key":"993_CR54","first-page":"1463","volume":"22","author":"D Witte","year":"2002","unstructured":"Witte D, Thomas A, Ali N, et al. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res. 2002;22:1463\u20136.","journal-title":"Anticancer Res"},{"issue":"19","key":"993_CR55","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1158\/0008-5472.CAN-09-1693","volume":"69","author":"RT Kurmasheva","year":"2009","unstructured":"Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Can Res. 2009;69(19):7662\u201371.","journal-title":"Can Res"},{"issue":"3","key":"993_CR56","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21232","volume":"50","author":"M Maris","year":"2008","unstructured":"Maris M, Courtright J, Houghtonetal PJ. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50(3):581\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"993_CR57","first-page":"2991","volume":"34","author":"A Vilmar","year":"2014","unstructured":"Vilmar A, Santoni-Rugiu E, Garcia-Foncillas J, et al. Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer. Anticancer Res. 2014;34:2991\u20136.","journal-title":"Anticancer Res"},{"key":"993_CR58","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-12-1518","volume":"18","author":"J Thariat","year":"2012","unstructured":"Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, et al. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004\u201302). Clin Cancer Res. 2012;18:5123\u201333.","journal-title":"Clin Cancer Res"},{"key":"993_CR59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ghir.2010.03.001","volume":"20","author":"SK Singh","year":"2010","unstructured":"Singh SK, Tan QW, Brito C, et al. Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women. Growth Horm IGF Res. 2010;20:245\u201354.","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"993_CR60","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2350\/08-05-0477.1","volume":"12","author":"S Makawita","year":"2009","unstructured":"Makawita S, Ho M, Durbin AD, et al. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol. 2009;12(2):127\u201335.","journal-title":"Pediatr Dev Pathol"},{"issue":"7","key":"993_CR61","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-06-1344","volume":"67","author":"EF Petricoin","year":"2007","unstructured":"Petricoin EF, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt\/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Can Res. 2007;67(7):3431\u201340.","journal-title":"Can Res"},{"issue":"5","key":"993_CR62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1054\/ghir.2001.0244","volume":"11","author":"D Ayalon","year":"2001","unstructured":"Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3- FKHR oncoprotein. Growth Hormon IGF Res. 2001;11(5):289\u201397.","journal-title":"Growth Hormon IGF Res"},{"key":"993_CR63","first-page":"1063","volume":"5","author":"D Giri","year":"1999","unstructured":"Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic broblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999;5:1063\u201371.","journal-title":"Clin Cancer Res"},{"key":"993_CR64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/gcc.2870070407","volume":"7","author":"C Theillet","year":"1993","unstructured":"Theillet C, Adelaide J, Louason G, et al. FGFRI and PLAT genes and DNA amplication at 8p12 in breast and ovarian cancers. Genes Chromosom Cancer. 1993;7:219\u201326.","journal-title":"Genes Chromosom Cancer"},{"key":"993_CR65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/scitranslmed.3001451","volume":"2","author":"J Weiss","year":"2010","unstructured":"Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2:62\u201393.","journal-title":"Sci Transl Med"},{"key":"993_CR66","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/0bfaecca-0f87-43fe-97cc-f2ae3ddeb6d5","volume":"7","author":"SA Byron","year":"2012","unstructured":"Byron SA, Gartside M, Powell MA, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE. 2012;7: e30801.","journal-title":"PLoS ONE"},{"key":"993_CR67","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ajhg.2008.02.008","volume":"82","author":"AC Antoniou","year":"2008","unstructured":"Antoniou AC, Spurdle AB, Sinilnikova OM, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82:937\u201348.","journal-title":"Am J Hum Genet"},{"key":"993_CR68","first-page":"3541","volume":"61","author":"JH Jang","year":"2001","unstructured":"Jang JH, Shin KH, Park JG. Mutations in broblast growth factor receptor 2 and broblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001;61:3541\u20133.","journal-title":"Cancer Res"},{"key":"993_CR69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/path.1202","volume":"198","author":"BW Van Rhijn","year":"2002","unstructured":"Van Rhijn BW, Montironi R, Zwartho EC, et al. Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 2002;198:245\u201351.","journal-title":"J Pathol"},{"key":"993_CR70","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","volume":"16","author":"M Chesi","year":"1997","unstructured":"Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of broblast growth factor receptor 3. Nat Genet. 1997;16:260\u20134.","journal-title":"Nat Genet"},{"issue":"11","key":"993_CR71","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/gcc.20489","volume":"46","author":"M Goldstein","year":"2007","unstructured":"Goldstein M, Meller I, Orr-Urtreger A. FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5\u2032 CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chromosom Cancer. 2007;46(11):1028\u201338.","journal-title":"Genes Chromosom Cancer"},{"issue":"12","key":"993_CR72","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/sj.bjc.6605407","volume":"101","author":"M Hirotsu","year":"2009","unstructured":"Hirotsu M, Setoguchi T, Matsunoshita Y, et al. Tumour formation by single fibroblast growth factor receptor 3- positive rhabdomyosarcoma-initiating cells. Br J Cancer. 2009;101(12):2030\u20137.","journal-title":"Br J Cancer"},{"issue":"11","key":"993_CR73","first-page":"3395","volume":"119","author":"JG Taylor","year":"2009","unstructured":"Taylor JG, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Investig. 2009;119(11):3395\u2013407.","journal-title":"J Clin Investig"},{"key":"993_CR74","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/14728220902719233","volume":"13","author":"AM Oseini","year":"2009","unstructured":"Oseini AM, Roberts LR. PDGFR alpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert OpinTher Targets. 2009;13:443.","journal-title":"Expert OpinTher Targets"},{"key":"993_CR75","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0065-230X(06)97011-0","volume":"97","author":"A Ostman","year":"2007","unstructured":"Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007;97:247.","journal-title":"Adv Cancer Res"},{"key":"993_CR76","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1101\/gad.1972310","volume":"24","author":"T Ozawa","year":"2010","unstructured":"Ozawa T, Brennan CW, Wang L, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 2010;24:2205.","journal-title":"Genes Dev"},{"key":"993_CR77","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1007\/s00018-004-4272-z","volume":"61","author":"AV Jones","year":"2004","unstructured":"Jones AV, Cross NC. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci. 2004;61:2912.","journal-title":"Cell Mol Life Sci"},{"key":"993_CR78","first-page":"2178","volume":"39","author":"S Fujino","year":"2018","unstructured":"Fujino S, Miyoshi N, Ohue M, et al. Platelet-derived growth factor receptor-\u03b2 gene expression relates to recurrence in colorectal cancer. Oncol Rep. 2018;39:2178\u201384.","journal-title":"Oncol Rep"},{"issue":"10","key":"993_CR79","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/cncr.23038","volume":"110","author":"PM Armistead","year":"2007","unstructured":"Armistead PM, Salganick J, Roh JS, et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer. 2007;110(10):2293\u2013303.","journal-title":"Cancer"},{"issue":"3","key":"993_CR80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/pbc.20466","volume":"46","author":"MC Blandford","year":"2006","unstructured":"Blandford MC, Barr FG, Lynch JC, et al. Rhabdomyosarcomas utilize devel- opmental, myogenic growth factors for disease advantage: a report from the children\u2019s oncology group. Pediatr Blood Cancer. 2006;46(3):329\u201338.","journal-title":"Pediatr Blood Cancer"},{"issue":"51","key":"993_CR81","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/onc.2008.255","volume":"27","author":"E Taniguchi","year":"2008","unstructured":"Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR- a is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2008;27(51):6550\u201360.","journal-title":"Oncogene"},{"issue":"19","key":"993_CR82","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1200\/JCO.2008.20.5054","volume":"27","author":"R Chugh","year":"2009","unstructured":"Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27(19):3148\u201353.","journal-title":"J Clin Oncol"},{"key":"993_CR83","doi-asserted-by":"crossref","first-page":"26465","DOI":"10.18632\/oncotarget.8417","volume":"7","author":"P Griseri","year":"2016","unstructured":"Griseri P, Garrone O, Sardo AL, et al. Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients. Oncotarget. 2016;7:26465\u201379.","journal-title":"Oncotarget"},{"key":"993_CR84","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/147323000803600406","volume":"36","author":"Q Zeng","year":"2008","unstructured":"Zeng Q, Cheng Y, Zhu Q, et al. The Relationship between over-expression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res. 2008;36:656\u201364.","journal-title":"J Int Med Res"},{"key":"993_CR85","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-17-0528","volume":"23","author":"K Ban","year":"2017","unstructured":"Ban K, Feng S, Shao L, et al. RET signaling in prostate cancer. Clin Cancer Res. 2017;23:4885\u201396.","journal-title":"Clin Cancer Res"},{"key":"993_CR86","doi-asserted-by":"publisher","DOI":"10.3109\/10715761003667554","author":"GY Liou","year":"2010","unstructured":"Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010. https:\/\/doi.org\/10.3109\/10715761003667554.","journal-title":"Free Radic Res"},{"issue":"15_suppl","key":"993_CR87","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1200\/JCO.2019.37.15_suppl.9005","volume":"37","author":"PK Paik","year":"2019","unstructured":"Paik PK, Veillon R, Cortot AB, et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. J Clin Oncol. 2019;37(15_suppl):9005.","journal-title":"J Clin Oncol"},{"key":"993_CR88","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383:931\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"993_CR89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang Q, Yang S, Wang K, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;12(1):63.","journal-title":"J Hematol Oncol"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-023-00993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-023-00993-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-023-00993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T01:14:24Z","timestamp":1704330864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-023-00993-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s13577-023-00993-5","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted after approval from the Institute Ethics Committee, AIIMS, New Delhi Ref No IEC-45\/02.02.2018,RP-02\/2018.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}